Category Archives: Gene Therapy

Albany, NY (PRWEB) February 01, 2015 The new report is titled Recombinant Coagulation Factors 2015: Maturation of Recombinant Clotting Factor Pipeline and Emergence of Gene Therapy and Alternative Procoagulants and deals with historical statistics and future projections regarding the recombinant coagulation factors market. It gathers data from 2013 and the first three quarters of 2014 to analyze the development of the market through the two years. It focuses strongly on pipeline products in the market. To get sample report with TOC Click Here: http://www.researchmoz.com/enquiry.php?type=sample&repid=241916 Recombinant coagulation factors are used in diseases such as hemophilia A and B, to bring about blood coagulation when the patients natural capacity to do so has been hampered. Market data for various classes of recombinant coagulation factors such as factors VII, VIII, and IX are analyzed in the research report, along with an examination of the development of other nascent and comparatively untouched substances and methods such as alternative procoagulants, immune tolerance-inducing agents, and gene therapeutics. The report profiles the competitive landscape in detail and provides special attention to the impact of new products on the respective positions of major players of the market. This helps gain insight into the short-to-mid-term future of the market. … Continue reading →

JSB Market Research: Gene Therapy Immunology Insight Gene Therapy Immunology Insight: Pipeline Assessment, Technology Trend, and Competitive Landscape provides the information across the gene therapy value chain covering gene therapy profiles... By: Kalyani Roy … Continue reading →

Prof Wang Bin - Bio Gene Therapy By: Kelvin Kwek CT … Continue reading →

Anna David, Prenatal Cell and Gene Therapy Anna David, Prenatal Cell and Gene Therapy (Research Department of Maternal and Fetal Medicine, UCL EGA Institute for Women's Health) talks about her group's research. By: UCL EGA Institute for Women's Health … Continue reading →

Gene Therapy Pioneer Ted Friedman Awarded Japan Prize Theodore Friedmann, MD, professor in the Department of Pediatrics at University of California, San Diego School of Medicine has been named a 2015 recipient... By: UC San Diego Health System … Continue reading →

Dr. Theodore Friedmann is a longtime faculty member at UC San Diego and a pioneer in gene therapy. / photo by Nelvin C. Cepeda * U-T San Diego Dr. Theodore Friedmann, a pioneer in the booming field of gene therapy, has been named a 2015 winner of the prestigious Japan Prize. A pediatrician-turned-researcher at UC San Diego, Friedmann is renowned for demonstrating in the lab that it is possible to correct a genetic defect by adding a functional gene to defective cells, a feat he and colleagues accomplished in 1968. Since then, Friedmann has been guiding the young science through controversies, ethical challenges and setbacks. Friedmann shares the prize in "medical science and medicinal science" with Dr. Alain Fischer of the Necker Hospital in Paris, France. Fischer helped demonstrate gene therapy's clinical ability to treat a genetic immune deficiency that makes patients extremely vulnerable to infections. Along with the recognition, Friedmann and Fischer will split a $416,600 award, a certificate and gold medal. There's also the prospect of future recognition: several Japan Prize winners have gone on to win the Nobel Prize. Friedmann is known not only as a scientist who demonstrated gene therapy is possible, but as a thinker … Continue reading →

Contact Information Available for logged-in reporters only Newswise Theodore Friedmann, MD, professor in the Department of Pediatrics at University of California, San Diego School of Medicine was named today one of three recipients of the 2015 Japan Prize, a prestigious international award honoring laureates whose original and outstanding achievements in science and technology have advanced the frontiers of knowledge and served the cause of peace and prosperity for mankind. Friedmann is being recognized for his pioneering research and contributions to the development of gene therapy, a new field of medicine which in significant ways originated at UC San Diego. The sponsoring Japan Prize Foundation describes Friedmann as the father of gene therapy. Sharing the 2015 Japan Prize in the field of medical science and medicinal science with Friedman is Alain Fischer, MD, PhD, director of immunology at the Necker Hospital in Paris, France. Fischer is credited with demonstrating the clinical efficacy of gene therapy by successfully treating children suffering from a severe genetic disorder that renders them extremely vulnerable to infections. The third 2015 Japan Prize laureate is Yutaka Takahasi, PhD, professor emeritus at the University of Tokyo, who is being honored in the field of resources, energy and social … Continue reading →

DUBLIN, January 27, 2015 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/pfd99m/recombinant) has announced the addition of the "Recombinant Coagulation Factors 2015: Maturation Of Recombinant Clotting Factor Pipeline And Emergence Of Gene Therapy And Alternative Procoagulants" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) A Pipeline Landscape Analysis and Comparative Assessment of Key Players This report provides an update of recombinant coagulation factors used for controlling bleeding of hemophilia A and B and other bleeding disorders. 2013 sales figures and 2014 nine-month sales data are analyzed to evaluate commercial development of the market under the light of a strong pipeline and entry of new competitor products into the market. The profiles of drug candidates in development are presented in details not only for recombinant coagulation factors VIII, IX and VII, but also for emerging alternative procoagulants, gene therapeutics and immune tolerance inducing agents. The competitve landscape of classical recombinant coagulation factors and of new emerging treatment modalities of hemophilia and other severe bleeding orders is analyzed. The emergence of new treatment modalities brings many new stakeholders to the field of hemophilia. Among them are the established hemophilia portofolio companies, but also new entrants from Big Pharma and Big Biotech, specialty pharmaceutical companies, biosimilar … Continue reading →

Flagship Journal Current Gene Therapy A short promotional video of Bentham Science High Impact Journal Current Gene Therapy. By: Bentham Science Publishers … Continue reading →

lily and america gene therapy By: America Evans … Continue reading →